Organizer Profile
Aerie Pharmaceuticals

Aerie Pharmaceuticals

Durham, North Carolina, United States of America

ABOUT

We are a publicly traded (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye.

Our first product, Rhopressa (netarsudil ophthalmic solution) 0.02%, was approved by the United States Food & Drug Administration (FDA) in December 2017 for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Our second product, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, is a fixed dose combination of Rhopressa® and latanoprost, a widely prescribed prostaglandin analogue (PGA). We expect to file our NDA for Roclatan™ in the second quarter of 2018. If approved, we believe Roclatan™ has the potential to be the most efficacious therapy for lowering of elevated IOP in the marketplace.